At present, pharmacokinetic aspects in existing in vitro assays for cytotoxic drug screening are considered only insufficiently. Using a new microperfusion assay, we integrated the peak plasma concentration (Cmax), the time of peak concentration (t max), the absorption rate, and the elimination rate following methotrexate (MTX) treatment of L1210 leukemic cells in vitro. The effects of different MTX concentration courses with constant exposure doses (area under the concentration-time curve) were checked by combining the microperfusion assay with the clonogenic assay in agar-containing glass capillaries. We found that the concentration profiles obtained in the ultrafiltration-flat chamber (an essential part of the microperfusion system) can be described by the Bateman function. Thus, the flat chamber might be comprehended as a one-compartmental system with first-order absorption kinetics. We found that the colony-inhibition kinetics of L1210 cells obviously depended on the MTX exposure profile. Continuous cell-growth inhibition was obtained by one concentration profile that offered a compromise between all pharmacokinetic parameters. Our results correlated with the known pharmacodynamic activities of MTX and showed the relevance of different concentration courses to the cytotoxic effect of the drug. We suppose that the growth-inhibition kinetics of unknown, potential anticancer drugs can be also interpreted in similar ways.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Adams DJ (1989) In vitro pharmacodynamic assay for cancer drug development: application to Crisnatol, a new DNA intercalator. Cancer Res 49: 6615–6620
Cohen M, Bender RA, Donehower R, Myers CE, Chabner BA (1978) Reversibility of high-affinity binding of methotrexate in L1210 murine leukemia cells. Cancer Res 38: 2866–2870
Derendorf H, Garrett ER (1987) Pharmakokinetik. Wissenschaftliche Verlagsgesellschaft, Stuttgart
Ellner PD, Neu HC (1981) The inhibitory quotient: a method for interpreting minimum inhibitory concentration data. JAMA 246: 1575–1578
Gimmel S, Maurer HR (1994) Concentration- and time-dependent cytostatic effects of methotrexate and etoposide on L1210 leukemia cells in vitro demonstrated by a new microperfusion method. Anticancer Res (in press)
Gimmel S, Kinawi A, Maurer HR (1993) A new microperfusion system for the cultivation of tumor cells in vitro: approach to integrate pharmacokinetic parameters in screening assays for cytostatic drugs. Int J Oncol 2: 39–46
Goldman ID (1975) Analysis of the cytotoxic determinants for methotrexate (NSC-740): a role for free intracellular drug. Cancer Chemother Rep 6: 51–61
Henderson GB, Zevely EM (1984) Transport routes utilized by L1210 cells for the influx and efflux of methotrexate. J Biol Chem 259: 1526–1531
Kinawi A, M-Ali H (1990) Modifizierung der Flachkammer-Methode für die Bestimmung der Bindung von Pharmaka an Humanserumalbumin. Arch Pharm 323: 523–524
Kinawi A, Teller C (1979) Zur Bestimmung der Pharmaka-Albuminbindung in Pufferlösung mit Hilfe eines modifizierten Ultrafiltrationsverfahrens. Arzneimittelforschung 29: 1495–1500
Liliemark J, Peterson C (1991) Pharmacokinetic optimization of anticancer therapy. Clin Pharmacokinet 21: 213–231
Maurer HR, Echarti C (1990) Clonogenic assays for hematopoietic and tumor cells using agar-containing capillaries. In: Pollard JW, Walker JM (eds) Methods in molecular biology, vol 5. Animal cell culture. Humana, Clifton, pp 379–394
Moore RD, Lietman PS, Smith CR (1987) Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155: 93–99
Roper PR, Drewinko B (1976) Comparison of in vitro methods to determine drug-induced cell lethality. Cancer Res 36: 2182–2188
Schentag JJ, Nix DE, Adelman MH (1991) Mathematical examination of dual individualization principles. I. Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacine, and tobramycine. Drug Intell Clin Pharm 25: 1050–1057
Schlemmer SR, Sirotnak FM (1992) Energy-dependent efflux of methotrexate in L1210 leukemia cells. J Biol Chem 267: 14746–14752
Schornagel JH, McVie JG (1983) The clinical pharmacology of methotrexate. Cancer Treat Rev 10: 53–75
Sirotnak FM, Donsbach RC (1976) Kinetic correlates of methotrexate transport and therapeutic responsiveness in murine tumors. Cancer Res 36: 1151–1158
Wheeler KT, Levin VA, Deen DF (1978) The concept of drug dose for in vitro studies with chemotherapeutic agents. Radiat Res 76: 441–458
White CJ (1979) Reversal of methotrexate binding to dihydrofolate reductase by dihydrofolate. J Biol Chem 254: 10889–10895
About this article
Cite this article
Gimmel, S., Maurer, H.R. Growth kinetics of L1210 leukemic cells exposed to different concentration courses of methotrexate in vitro. Cancer Chemother. Pharmacol. 34, 351–355 (1994). https://doi.org/10.1007/BF00686044
- In vitro microperfusion system
- L1210 cells
- Pharmacokinetic parameters